We are live on ! Find out more
EXAS

Exact Sciences

Delisted

EXAS was delisted on the 20th of March, 2026.

559 hedge funds and large institutions have $11.5B invested in Exact Sciences in 2022 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 189 increasing their positions, 187 reducing their positions, and 84 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding in top 10

Funds holding in top 10: 68 (+2)

2.86% more ownership

Funds ownership: 93.29%96.16% (+2.9%)

1% more repeat investments, than reductions

Existing positions increased: 189 | Existing positions reduced: 187

6% less funds holding

Funds holding: 596559 (-37)

8% less capital invested

Capital invested by funds: $12.5B → $11.5B (-$995M)

20% less call options, than puts

Call options by funds: $128M | Put options by funds: $160M

36% less first-time investments, than exits

New positions opened: 54 | Existing positions closed: 84

Holders
559
Holders Change
-37
Holders Change %
-6.21%
% of All Funds
8.82%
Holding in Top 10
8
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+33.33%
% of All Funds
0.13%
New
54
Increased
189
Reduced
187
Closed
84
Calls
$128M
Puts
$160M
Net Calls
-$31.6M
Net Calls Change
+$5.19M
Name Holding Trade Value Shares
Change
Change in
Stake
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$1.34B +$394M +5,392,099 +39%
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.09B +$15.4M +210,260 +1%
AIM
3
ARK Investment Management
Florida
$1B +$60.5M +827,948 +6%
Wellington Management Group
4
Wellington Management Group
Massachusetts
$877M +$114M +1,553,934 +14%
BlackRock
5
BlackRock
New York
$684M +$21.4M +292,540 +3%
Sumitomo Mitsui Trust Group
6
Sumitomo Mitsui Trust Group
Japan
$394M -$18.4M -251,836 -4%
Capital World Investors
7
Capital World Investors
California
$384M +$58.8M +804,159 +17%
JP Morgan Chase
8
JP Morgan Chase
New York
$368M +$39.3M +537,107 +11%
NAMA
9
Nikko Asset Management Americas
New York
$361M -$18.6M -254,335 -5%
State Street
10
State Street
Massachusetts
$315M +$18.1M +247,246 +6%
Baillie Gifford & Co
11
Baillie Gifford & Co
United Kingdom
$305M -$13.5M -185,274 -4%
Ameriprise
12
Ameriprise
Minnesota
$194M -$73.3M -1,002,095 -27%
SCM
13
Spyglass Capital Management
California
$166M -$21.2M -289,763 -11%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$158M +$6.74M +92,267 +4%
EC
15
Eminence Capital
New York
$157M -$40.7K -557 -0%
Ensign Peak Advisors
16
Ensign Peak Advisors
Utah
$157M -$10.7M -146,764 -6%
Invesco
17
Invesco
Georgia
$138M +$2.27M +31,061 +2%
CS
18
Credit Suisse
Switzerland
$110M -$38.1M -521,297 -25%
ZCI
19
Zevenbergen Capital Investments
Washington
$107M -$6.42M -87,766 -5%
EAM
20
Eventide Asset Management
Massachusetts
$104M
GGHC
21
Gilder Gagnon Howe & Co
New York
$96.8M -$1.76M -24,076 -2%
CC
22
Casdin Capital
New York
$93M -$51.9M -710,000 -35%
Amundi
23
Amundi
France
$90.2M -$62.9M -860,298 -40%
Morgan Stanley
24
Morgan Stanley
New York
$88.9M +$28.9M +395,098 +45%
Norges Bank
25
Norges Bank
Norway
$80.8M -$21.5M -293,452 -20%

EXAS Hedge Fund Activity: Q1 2022 in Review

559 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Exact Sciences (EXAS) for Q1 2022, worth a combined $11.5B — down 8% from $12.5B a quarter earlier.

Sellers outnumbered buyers: 84 funds closed out of EXAS and 54 opened new positions — a net loss of 30 holders — while 187 trimmed existing stakes and 189 added.

The largest buyer was T. Rowe Price Associates, adding an estimated $394M. The largest seller was Ameriprise, cutting an estimated $73.3M.

  • 559 institutional investors held Exact Sciences (EXAS) as of Q1 2022, down from 596 in Q4 2021.
  • Funds reported $11.5B of Exact Sciences stock for Q1 2022, down 8% quarter-over-quarter.
  • 54 funds opened new Exact Sciences positions in Q1 2022 and 84 closed out, a net change of -30 holders.
  • The largest Exact Sciences buyer in Q1 2022 was T. Rowe Price Associates, an estimated $394M added.
  • The largest Exact Sciences seller in Q1 2022 was Ameriprise, an estimated $73.3M sold.

Based on aggregated 13F filings for Q1 2022.